Check out your Company Bowl for anonymous work chats.
At Verily, we believe that analyzing many different types of health data is key to deeply understanding diseases. Type 2 diabetes is a complex disease, making prevention, diagnosis, and monitoring complicated. New Verily-led research published in Nature Portfolio shows the potential to improve the identification of people at higher risk of developing diabetes by analyzing blood protein profiles. The 4-year study included participants with diverse backgrounds and a wide range of health states from the Project Baseline Health Study. Researchers concluded that understanding diabetes at the molecular level can help refine diagnostic approaches and personalized treatment efforts. Read more detailed methods and findings: https://www.nature.com/articles/s43856-025-00964-x
Supporting better nutrition for individuals managing cardiometabolic conditions is more important — and more challenging — than ever. Explore Verily’s latest Research Insights paper, introducing a novel, evidence-based framework to make it easier: the 3Ps Approach — Practical, Positive, Personalized.
The Verily platform harmonizes and curates complex datasets, enabling advanced analytics and the deployment of healthcare AI models. We’re helping life sciences and pharma companies accelerate therapies and empowering health systems and payers to improve outcomes while reducing costs.
For people living with type 2 diabetes, like Nini, better care requires supporting their lifestyle changes. Watch how Verily is using AI to help clinicians and care teams prioritize higher risk patients and personalize care plans: https://verily.com/n-of-1
🚀 Introducing a new Verily tech blog series giving you an in-depth look at how our product engineers are making healthcare data AI-ready and powering innovations to realize the promise of precision health. Read the inaugural blog post about why and how Verily uses FHIRPath, ensuring clinicians, engineers, product teams, and data informaticists can speak the same healthcare data language.
Happy Fourth of July from all of us at Verily! Our US offices will be closed as we celebrate the 249th birthday of the United States 🇺🇲
Our CEO Stephen Gillett shared his mid-year prediction with Brittany Trang of STAT on what we can expect for AI in healthcare in 2025. He’s optimistic about the role AI agents will play in improving care 👇
Verily’s wastewater monitoring program provides real-time public health insights and early warning of virus levels in communities. Here’s what we learned in recent months: ➡ ️ C. auris, a drug-resistant fungus that causes severe illness and spreads among patients in healthcare settings, is an emerging threat across the Midwestern United States. ➡ Pathogen trend data can be extremely valuable in smaller, high-risk communities, such as hospitals or care facilities, due to Verily’s rapid reporting of data to customers.
🧠 Nutrition behavior change is complex — especially for individuals managing cardiometabolic conditions. 📊 From recent research, Verily derived the 3Ps framework — Practical, Positive, Personalized — a novel approach with AI-enhanced nutrition support within the Verily Lightpath virtual chronic care solution. 📄 Check out our blog to see how smarter support and tools can inspire behavior change for better outcomes — health and costs.
What a fantastic week at DIA 2025! We enjoyed participating in discussions on wearable health technologies and digital protocols, and how these innovations are advancing clinical research. Huge thanks to our speakers, Sooyoon Shin, Yugang Jia, Ph.D MPH, and Travis Hanly for sharing their expertise. Key insight: Streamlining workflows and accelerating trials through digital protocols is a key opportunity for study sponsors.
